FDA approves AbbVie's $59K rheumatoid arthritis drug

The FDA has approved Rinvoq, a once-daily oral pill for the treatment of moderate to severe rheumatoid arthritis. 

AbbVie, the maker of Rinvoq, plans to launch the product in the U.S. in late August with a price tag of $59,000 per year, according to Reuters.

Rinvoq belongs to a class of medications known as JAK inhibitors that block enzymes that cause inflammation.

The FDA approval comes as a big boost for AbbVie, which is facing generic competition for its older blockbuster rheumatoid arthritis treatment Humira. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like